Fluicell (5J90) Stock Overview
A life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
5J90 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Fluicell AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.80 |
| 52 Week High | SEK 5.22 |
| 52 Week Low | SEK 0.72 |
| Beta | 2.01 |
| 1 Month Change | -13.04% |
| 3 Month Change | 137.29% |
| 1 Year Change | 270.86% |
| 3 Year Change | -93.10% |
| 5 Year Change | -99.64% |
| Change since IPO | -99.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5J90 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -12.5% | -0.1% | 0.1% |
| 1Y | 270.9% | -26.5% | -0.5% |
Return vs Industry: 5J90 exceeded the German Medical Equipment industry which returned -25.4% over the past year.
Return vs Market: 5J90 exceeded the German Market which returned 0.3% over the past year.
Price Volatility
| 5J90 volatility | |
|---|---|
| 5J90 Average Weekly Movement | 24.5% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 5J90's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5J90's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 11 | Carolina Trjulja | www.fluicell.com |
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that produces single cell arrays to organoids and complex tissues; Nexocyte, a platform for universal tissue production; and Biopixlar AER, a single-cell bioprinting platform that fits into a biosafety cabinet.
Fluicell AB (publ) Fundamentals Summary
| 5J90 fundamental statistics | |
|---|---|
| Market cap | €3.75m |
| Earnings (TTM) | -€212.17k |
| Revenue (TTM) | €1.82m |
Is 5J90 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5J90 income statement (TTM) | |
|---|---|
| Revenue | SEK 20.15m |
| Cost of Revenue | SEK 2.06m |
| Gross Profit | SEK 18.09m |
| Other Expenses | SEK 20.44m |
| Earnings | -SEK 2.35m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 21, 2026
| Earnings per share (EPS) | -1.71 |
| Gross Margin | 89.76% |
| Net Profit Margin | -11.65% |
| Debt/Equity Ratio | 0% |
How did 5J90 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/22 22:05 |
| End of Day Share Price | 2026/07/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fluicell AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.